At 22.3x earnings and 15.7x forward earnings, the market is pricing BUD as a moderate-growth consumer staple, yet the 1.5 Altman Z-Score signals balance sheet fragility that does not align with a defensive multiple. A PEG Forward of 1.9 implies growth is not cheap, especially with Return on Equity at just 3.80% and Operating Margin at 4.10%, both underwhelming for a global brewer. The 15.7 Forward P/E suggests earnings expansion is expected, but with an Altman score in the distress zone and a Current Ratio of 0.7, the valuation embeds optimism that the balance sheet does not fully justify. This is not a screaming mispricing; it is a cautiously priced turnaround with financial risk embedded beneath a consumer defensive label.